Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06989112 |
Title | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01) |
Acronym | DE-01 |
Recruitment | Recruiting |
Gender | female |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | AstraZeneca |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS |